Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436 CH)
Watchlist
100
Analysis
Health Care
•
China
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. manufactures and markets Chinese traditional medicines, including Pientzehuang, Pientzehuang capsules, Pientzehuang lozenge, cough syrup, and other related products.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Quantitative Analysis
•
01 Dec 2025 14:30
CSI 100 Index Earning Revision (Nov): CHINA VANKE, PING AN INSURANCE, BOE, TCL
We analyzed CSI 100's consensus for Nov 2025 and highlighted changes of EPS in CHINA VANKE (000002 CH), PING AN INSURANCE (601318 CH), BOE...
Ke Yan, CFA, FRM
Follow
436 Views
Share
bullish
•
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
•
23 Sep 2025 10:49
Primer: Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436 CH) - Sep 2025
Dominant Market Position Solidified by State Protection: Zhangzhou Pientzehuang's core product, the Pientzehuang series, is a Class-1 protected...
αSK Primers
115 Views
Share
bullish
•
Jiangsu Hengrui Medicine
•
08 Jan 2025 07:03
Jiangsu Hengrui Pharma (600276 CH): Index Inclusion Post H-Share Listing
Jiangsu Hengrui has filed an application proof for an HKEX listing. Reports indicate a US$2bn raise. There will be no index Fast Entry but...
Brian Freitas
Follow
1.3k Views
Share
bullish
•
Seres Group
•
01 Dec 2024 15:28
Quiddity SSE50/180 Dec 24 Results: All SSE 50 ADDs in the LONGs Basket; Positive Start; More to Come
All five SSE 50 ADDs are in our previous LONGs basket. Since 5th Nov, the LONGs have outperformed the index by 2.7% which was a better return than...
Janaghan Jeyakumar, CFA
Follow
752 Views
Share
bullish
•
Seres Group
•
01 Dec 2024 09:30
SSE50/SSE180 Index Rebalance: Couple of Surprises; Seres Group's Multiple Inclusions; US$3.2bn Trade
5/18 changes for the SSE50/180 in Dec. Seres Group is an add to both indices and the CSI300, so plenty to buy there. Couple of other surprises. The...
Brian Freitas
Follow
815 Views
Share
First
Previous
6
7
8
9
10
11
12
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x